IMPORTANCE Voice prosthesis (VP) device life is a limiting factor of tracheoesophageal (TE) voice restoration that drives patient satisfaction, health care costs, and overall burden. Historic data suggest that TE VPs have an average device life of generally 3 to 6 months, but these data are typically derived from small samples using only 1 or 2 devices. OBJECTIVE To reexamine current device life in a large, contemporary cancer hospital in the United States that uses a wide assortment of VPs. 
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Supplemental content at jamaotolaryngology.com T racheoesophageal (TE) speech is regarded as the gold standard for rehabilitation following total laryngectomy 1 and is considered a superior method to esophageal speech and the use of an electrolarynx in properly selected patients. 2 Tracheoesophageal speech utilizes a voice prosthesis (VP) that is inserted through a puncture in the common wall separating the trachea from the esophagus. As the speaker occludes the stoma, air from the lungs is forced through the prosthesis via a one-way valve, causing the pharyngoesophageal segment to vibrate. This vibration egresses into the oral cavity, and the articulators move to create speech. The VP allows air exchange into the pharyngoesophagus for speech production while preventing aspiration of food and liquid into the lungs. Over the years, manufacturers have produced an assortment of TE VPs that vary in length, diameter, valve strength, material, and insertion method. Voice prostheses are commonly distinguished using 2 categories: nonindwelling and indwelling devices. Properly trained patients or others may insert nonindwelling devices to allow for greater independence and minimize the number of return clinic visits. Speech language pathologists, physicians, or other trained clinicians must place indwelling devices. 3 Indwelling devices are considered for patients who experience frequent leakage through nonindwelling VPs or for those who are unable or do not wish to exchange their own devices. 4 The most commonly cited cause of device failure is leakage of liquids through the prosthesis, a problem often attributed to the formation of biofilm on the valve. Although the current literature is limited, other factors may influence device life, including cancer type and extent of treatment. 5 Recent manufacturing advances in TE VPs have focused on the enhancement of device function and prolongation of device life or time to device failure. Such advances include the use of magnets in the prosthesis valve to increase valve resistance 6 and the incorporation of specialty biomaterials such as silver oxide to reduce biofilm formation. 7 The duration of VPs can have substantial effects on patient burden including cost, frequency of clinic visits, and overall quality of life, 6 making new and improved specialty VPs an attractive option to improve the health and overall satisfaction of TE speakers. Historical data suggest an average lifetime of 4 to 6 months for most indwelling VPs, but these data have not been revisited in a contemporary practice in which total laryngectomy is often performed as a salvage procedure after radiation failure. Limited data have been published comparing various VPs, especially with regard to their relative device lifetimes, and the existing data show conflicting results. 8, 9 The purpose of this 10-year retrospective analysis was to (1) estimate device life in a contemporary cohort of TE voice prosthesis users and (2) examine the treatment and prosthetic-related factors that influence device failure.
Methods

Study Methods and Eligibility
An institutional review board-approved retrospective study was completed using records of 390 patients who underwent a total laryngectomy with a TE puncture (TEP) and who had VP management at MD Anderson Cancer Center (MDACC) between July 1, 2003, and December 31, 2013. A waiver of informed consent was obtained. Data were collected from the MDACC TEP tracking database and by review of electronic medical records. Eligibility criteria included a record of VP placement in the MDACC TEP tracking database of patients who underwent total laryngectomy, total laryngectomy with partial pharyngectomy, or total laryngopharyngectomy and whose prosthesis management took place at MDACC during the study period. Records of dummy prostheses, records with incomplete durational data, records of prostheses that were placed within 90 days after TEP whose exchange was likely influenced by change in tract length during early postsurgical healing rather than device failure due to leakage, records postdating recurrent disease after TEP, records of patients presenting to the clinic with dislodged VPs for which duration was unclear, and records of patients who required temporary prosthesis removal prior to procedures (ie, dilation and TE injection) were excluded from analysis. Additionally, records with incomplete durational data based on patient self-replacement of their own prostheses and records with non-MDACC replacement data were also excluded.
Institutional TEP Management
Both primary and secondary TEP are performed at MDACC. A variety of indwelling and nonindwelling TE VPs are used within the institution (InHealth Technologies; Atos Medical). Nonindwelling devices were defined as those cleared by the US Food and Drug Administration (FDA) for insertion by the patient at home. Indwelling devices were defined as those FDA-cleared for insertion by a clinician. Specialty devices were defined as those designed and manufactured to address the need for a stronger, more durable device with increased resistance to airflow. Types of prostheses used in this study are listed and categorized in eTable 1 in the Supplement.
Statistical Analysis
Voice prothesis duration was summarized using descriptive methods. Findings In this retrospective study of 390 laryngectomized patients with TE puncture (3648 total prosthesis replacements), median device life was 61 days for all prostheses. Most prostheses (69%) were replaced because of leakage. Neither radiation nor extent of surgery had a meaningful effect on device life.
Meaning Voice prothesis duration demonstrates lower durability than historically reported, highlighting the need for better voice prothesis design and proper patient counseling to ensure appropriate TE puncture candidate selection and accurate patient expectations for successful TE speech outcomes.
Results
Patient Population
The study population included 390 patients with a history of total laryngectomy and TEP who had VPs placed at MDACC between July 1, 2003, and December 31, 2013. 
Voice Prosthesis Characteristics
During the study period, 3648 prostheses were placed in the 390 patients. Indwelling prostheses accounted for over half of all devices placed (76%). The most common prosthesis placed was the Blom-Singer Indwelling (InHealth Technologies) (38%). Over half of the devices (55%) placed were 20 Fr in diameter, and the 2 most common lengths of prostheses were 8 mm (33%) and 10 mm (27%). Sixty-nine percent of prostheses were removed due to leakage, while the remainder were removed because of other etiologies unrelated to leakage. Nineteen percent of removals that included the prostheses of patients who requested replacement at the time of their physician return visit while at the clinic for regular surveillance as a matter of convenience regardless of problems were categorized as routinely related. Twelve percent were removed for nonleakage complications including extrusion, common wall swelling, gastric filling, or leakage around the prosthesis. Table 2 and the eTable 2 in the Supplement summarize device characteristics for all VPs.
Device Life Based on Patient Characteristics
Median (range) device life was 61 (1-816) days for all prostheses, and mean (SD) device life was 86 (87) days, as summarized in Figure 1 and Table 2 . Extent of surgery did not significantly affect device life; patients treated with total laryngectomy, total laryngectomy with partial pharyngectomy, and total laryngopharyngectomy had median lifetimes of 62, 57, and 56 days, respectively (P =.2 2 ) ( Figure 2A ).
There was a significant difference in prosthetic life in patients who had a history of radiation therapy (median, 59 days) compared with those who did not (median, 66 days), but this was on average only 1 week longer in duration than in the nonirradiated laryngectomy group ( Figure 2B ). Twenty five patients had subglottic disease or cervical esophageal extension necessitating lower surgical fields and possibly more distal location of TEP; VP duration was not significantly different among patients with subglottic disease relative to other sites (median: subglottic, 60 days vs other, 66 days; P = .19). There was a significant difference in prosthetic life based on timing of TEP (median: primary, 63 days vs secondary, 54 days; P = .003), but this represented less than 2 weeks in durational difference. Reason for VP removal significantly affected device life (P < .001), as shown in the eFigure in the Supplement. Patients whose prosthesis was removed for reasons other than leakage through the valve experienced poorer device life (median, 28 days) compared with prostheses that were removed for leakage through the valve (median, 64 days) or for prostheses regularly exchanged as part of routine clinic return visits (median, 61 days).
Device Life Based on Prosthesis Type
Indwelling VPs had significantly longer device life than nonindwelling types ( Figure 3A) . Device life did not differ significantly between specialty and standard VPs ( Figure 3B ). The VP with the longest life was the Provox ActiValve (Atos Medical) with a median of 161 days. eTable 3 in the Supplement shows a stratified summary of VP duration, and the survival curve in Figure 3C shows a comparison of all types of prostheses included in the study.
Sensitivity Analysis
A sensitivity analysis restricted to only the 2530 VPs that were removed for leakage demonstrated that inclusion of all prostheses in our comparative analyses of device life (including those changed in routine follow-up) did not alter our results.
Comparing results obtained in the 2530 VPs removed for leakage to all 3648 VPs, device life estimates among subgroups based on surgical extent, reconstruction, radiotherapy, TEP timing, and tumor site differed by only 1 to 7 days and statistical significance was unchanged for all comparisons.
Discussion
Voice prosthesis device life is a limiting factor of TE voice restoration. Device life drives patient satisfaction, health care costs, and overall rehabilitative burden. In this large, contemporary laryngectomy cohort of TE prosthesis users, the average device life was roughly 2 months, with minimal effects of treatment history and device type observed. Our device life results are lower than historic reports that are generally derived from small samples using only 1 or 2 devices, indicating typical device life between 3 and 6 months. Our results are comparable to those reported in a more recent 3-year European cohort of TE users that found a 3-month average duration (median, 74 days) of indwelling voice prostheses in a group of 102 laryngectomy survivors. 6 Both studies suggest a lower than previously estimated average of 4 to 6 months duration of VPs in contemporary users prior to TE prosthesis failure. 4, 10, 11 Accurate estimations of device life are critical to set realistic expectations for postlaryngectomy voice rehabilitation for both health care providers and patients. Preoperative counseling is considered best practice for the patient considering total laryngectomy with or without a TEP procedure. In these preoperative visits, it is customary to examine candidacy for TEP and to counsel the patient regarding expected outcomes and postoperative care. Collectively, ours and other recent device life studies suggest that, on average, the typical TE prosthesis user should anticipate roughly 4 to 6 prosthesis replacements within the calendar year. 6, 10, 11 This is a critical consideration for patients with limited access to expert providers trained in TE voice restoration. In addition, in countries in which health care is not universally provided, such as the United States, the cost associated with the replacement of TE voice prostheses may be an unexpected obstacle to successful TE voice restoration. Thus, the frequently held belief that The median device life of 3648 voice prostheses was 61 days. everyone is a candidate for TE voice restoration may be misleading. In our clinic setting, the translation of these data to our preoperative assessment algorithm is that it is now routine to include a frank discussion regarding the patient's ability and willingness to commit to regular return visits and potential costs associated with likely 4 to 6 new prostheses per year. Indwelling VPs were associated with significantly longer device life, but this was on average only a 1 month durational advantage. Despite the fact that indwelling prostheses are associated with longer device life and less burden for the patient in terms of self-management, there still may be advantages to the use of non-indwelling devices in some patients. Nonindwelling devices offer a more affordable option because the product is less expensive and does not require a clinic return that generates a hospital procedure charge, a cost advantage that is beneficial, regardless of the payer. These factors suggest that for select patients, the relative advantage of self-insertion of the nonindwelling device in lieu of the indwelling prosthesis may represent a worthwhile departure from current practice in which placement of the indwelling prosthesis has, in many cases, become the standard approach.
In most practices, factors related to radiation treatment and extent of surgery are commonly proposed as major drivers of device life; however, our data suggest otherwise. Although, our findings showed that radiotherapy was significantly associated with shorter device life, this outcome may simply represent a statistical but not a clinically meaningful difference since the median duration differed by only 7 days among radiated and nonirradiated TE speakers. Likewise, the extent of surgery was not statistically predictive of device life. We agree that radiotherapy and extent of surgery are important factors that influence the success of TE voice restoration and postlaryngectomy functioning and have been described robustly in areas related to TE voice quality, swallowing, and postlaryngectomy complication.
12-14 However, neither radiation nor extent of surgery showed any meaningful difference in device life in this study. Finally, a likely assumption that specialty designs of VPs, such as those that are manufactured with increased resistance to airflow or use antimicrobial materials among other substances, will result in better performance and therefore, facilitate longer time to device failure, may in fact be misleading. When the data from all indwelling devices was aggregated, our findings suggested that specialty indwelling prostheses did not outperform standard indwelling devices in terms of long-lasting device life. Rather they provided a similar duration comparable to the duration of standard devices used by normal, uncomplicated TE speakers. In other words, specialty prostheses are typically placed in patients who experience suboptimal device life using standard prostheses because of unique problems or characteristics related to physiology, anatomy, airflow, etc. 15, 16 Our results showed that specialty prostheses as a consortium, offered users an average duration comparable to standard devices, but they did not extend device life beyond the group level. That is, both the median device life for standard and specialty devices approximated 2 months. However, when data were examined based on individual performance, the ActiValve as an individual device offered the longest longevity relative to other VPs, representing a roughly 3-month longer duration beyond standard device life. This outcome is not unexpected but rather seems likely given the advanced design of a magnet-driven valve coupled with biofilm-resistant biomaterials. Unfortunately, despite the known benefit, the cost of the ActiValve makes it less accessible to patients in many health care settings. A better understanding of the relative benefit of specialty devices over their standard counterparts requires future controlled analysis comparing products using a within subject design to account for these selection biases.
Conclusions
Herein, we report to our knowledge the largest series to date examining VP device life in an unselected, contemporary cohort of TE speakers. Our data suggest that overall VP device life demonstrates a lower durability than historically has been reported, potentially representing the difficulties associated with comparison of studies in which methodologies and clinical practices differ and thus, conclusions are disparate. 
